Indirect Treatment Comparison of Long-Acting Injectable Cabotegravir as Pre-exposure Prophylaxis When Compared with no Pre-exposure Prophylaxis for HIV Prevention.

ABSTRACT:

Introduction

The efficacy of long-acting injectable cabotegravir (hereafter referred to as cabotegravir) versus daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for pre-exposure prophylaxis (PrEP) was demonstrated in two phase 3 randomized controlled trials (RCTs), HPTN 083 and HPTN 084. As these trials did not have a no-PrEP group, this analysis aimed to perform an indirect treatment comparison (ITC) of cabotegravir versus no PrEP via the common comparator of oral TDF/FTC.

Methods

A systematic literature review identifying trials of oral or both oral and injectable PrEP reporting HIV acquisition and oral PrEP adherence, measured by detectable TDF/FTC plasma levels, was conducted (November 1, 2023). Heterogeneity in oral TDF/FTC adherence level between trials

SUBMITTER: Hawkins N 

PROVIDER: S-EPMC12339807 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature